The Medical Advisor

Introduction Cancers of the female reproductive system, including ovarian, endometrial (uterine), and cervical cancers, represent a significant global health burden, often presenting at advanced stages with limited treatment options and poor prognosis. Conventional therapies such as chemotherapy, radiation, and surgery, while effective in some cases, frequently fail in recurrent or metastatic disease, prompting exploration of drug repurposing strategies.  This compilation examines emerging case reports on the off-label use of antiparasitic agents—primarily ivermectin and fenbendazole, alongside related benzimidazoles like mebendazole—in managing these malignancies. Drawing from 19 documented cases, the article categorizes outcomes by cancer type and integrates mechanistic insights from preclinical studies, where these compounds have demonstrated antitumor effects such as microtubule disruption, inhibition of oncogenic signaling pathways (e.g., PAK1, Wnt/β-catenin), induction of apo...